Pre-Filled Syringes West Coast

SMi Group reports: New participants confirmed to attend Pre-Filled Syringes West Coast Conference (June 4 – 5, San Diego, USA) - Glenmark Pharma, Xeris Pharma, Novo Nordisk, Subcuject APS, Ionis Pharmaceuticals, Regeneron, Antares Pharma. Preliminary list of attendees is released on the event official website - prefilled-syringes-westcoast (dot)com

Go to the profile of Lyudmyla Durneva
Apr 19, 2018

Key reasons to attend: 



This event is packed with market-led case studies and offers progressive insight into parenteral drug delivery.

Amongst topics covered: challenges of biopharmaceutical manufacturing in the PFS industry; economic benefits of Human Factors engineering; creating Design History Files; FDA’s expectations for HF validation of injector systems; pre-formative research of combination products + many others!


[Interactive on-site training – workshops on June 6]

-    How to leverage tangibles in user testing to ensure successful commercialisation of innovation products (iO Lifesciences);

-    Quality related aspects in creating digital connectivity for devices (AcceleratoRx, Temptime Corporation, The Plough Center, MedImmune Inc)


[Industry professionals under 1 roof]

With 5+ hours of networking, SMi’s Pre-Filled Syringes West Coast conference provides a perfect platform to build strategic partnerships and secure future collaborations. Attendees include: AbbVie, Allergan, Amgen, Aptar Pharma, Baxter Healthcare, Boehringer Ingelheim, Credence MedSystems, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Glenmark Pharmaceuticals, MedImmune Inc, Merck & Co., Pfizer CentreOne, Shire, Xeris Pharmaceuticals and many others!


Full agenda, list of speakers and information on participation options at



+44 (0)20 7827 6000


Twitter - @SMIpharm & #smipfsusa

LinkedIn - SMi Pharma



Pre-Filled Syringes West Coast | Conference: June 4 - 5th, 2018 | Interactive Workshops: June 6th, 2018


Go to the profile of Lyudmyla Durneva

Lyudmyla Durneva

Marketing Manager, SMi Group

No comments yet.